Abstract
Prion diseases are fatal neurodegenerative disorders that affect humans and other mammals. The hallmark of these diseases is the conformational change of the cellular prion protein (PrPC) to the misfolded protein capable of propagation and associated with neurodegeneration, named prion (PrPSc). In a strict sense, prion diseases are a consequence of aberrations in the metabolism of the cellular prion protein (PrPC). This brief review addresses current understanding of metabolic disturbances in prion disorders at the cellular, organ and organism level, selectively pointing out some relevant diagnostic and treatment options.
Keywords: Conformational diseases, metabolism, neurodegeneration, PrPC, PrPSc, transmissible spongiform encephalopathies, Prion diseases, Prion, Isoform, Glycoprotein, Misfolding proteins, Amyloid-β, PRNP gene, Translocation, Cytoplasm, Homeostasis, Olfactory discrimination, Embryogenesis, Truncations, Parkinson disease, Alzhemier disease, Tauopathies, Proteinopathies, Follicular dendritic cells, Lymphotoxin, Endocytosis, Monoclonal antibodies, Motif-grated antibodies, Epitope metabolism, ER stress, Oxidatie stress, Creutzfeldt-Jakob disease, Dementia, Myoclonus, Gerstmann-Straussler-Scheinker disease, Ataxia, Magnetic resonance spectroscopy, Pulvinar sign, Myoinositol, Gliosis, PET, Quinacrine, Swansonine, Darwinian evoluition, Anti-idiotypic antibodies
Current Drug Targets
Title: Metabolic Aspects of Prion Diseases: An Overview
Volume: 11 Issue: 10
Author(s): Tanja Vranac and Mara Bresjanac
Affiliation:
Keywords: Conformational diseases, metabolism, neurodegeneration, PrPC, PrPSc, transmissible spongiform encephalopathies, Prion diseases, Prion, Isoform, Glycoprotein, Misfolding proteins, Amyloid-β, PRNP gene, Translocation, Cytoplasm, Homeostasis, Olfactory discrimination, Embryogenesis, Truncations, Parkinson disease, Alzhemier disease, Tauopathies, Proteinopathies, Follicular dendritic cells, Lymphotoxin, Endocytosis, Monoclonal antibodies, Motif-grated antibodies, Epitope metabolism, ER stress, Oxidatie stress, Creutzfeldt-Jakob disease, Dementia, Myoclonus, Gerstmann-Straussler-Scheinker disease, Ataxia, Magnetic resonance spectroscopy, Pulvinar sign, Myoinositol, Gliosis, PET, Quinacrine, Swansonine, Darwinian evoluition, Anti-idiotypic antibodies
Abstract: Prion diseases are fatal neurodegenerative disorders that affect humans and other mammals. The hallmark of these diseases is the conformational change of the cellular prion protein (PrPC) to the misfolded protein capable of propagation and associated with neurodegeneration, named prion (PrPSc). In a strict sense, prion diseases are a consequence of aberrations in the metabolism of the cellular prion protein (PrPC). This brief review addresses current understanding of metabolic disturbances in prion disorders at the cellular, organ and organism level, selectively pointing out some relevant diagnostic and treatment options.
Export Options
About this article
Cite this article as:
Vranac Tanja and Bresjanac Mara, Metabolic Aspects of Prion Diseases: An Overview, Current Drug Targets 2010; 11 (10) . https://dx.doi.org/10.2174/1389450111007011207
DOI https://dx.doi.org/10.2174/1389450111007011207 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [ Hot topic: Aquaporins and Nervous System: from Bench to Bedside (Guest Editors: Rita Rezzani and Luigi F. Rodella) ]
Current Neuropharmacology Electroencephalography and Dementia: A Literature Review and Future Perspectives
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Drug Delivery & Formulation Editorial (Thematic Issue: Alzheimer’s Disease - Mechanisms, Drug Targets and Alternative Treatments)
Current Topics in Medicinal Chemistry Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias
CNS & Neurological Disorders - Drug Targets C-Peptide and its Correlation to Parameters of Insulin Resistance in the Metabolic Syndrome
CNS & Neurological Disorders - Drug Targets Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Novel Therapeutic Strategies in Major Depression: Focus on RNAi and Ketamine
Current Pharmaceutical Design Decline of Executive Processes Affects the Identification of Emotional Facial Expressions in Aging
Current Aging Science Role of Protein Conformational Dynamics and DNA Integrity in Relevance to Neuronal Cell Death in Neurodegeneration
Current Alzheimer Research Silencing the Brain May be Better than Stimulating it. The GABA Effect
Current Pharmaceutical Design Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets A Commentary on Neuronal Degeneration and Cell Death in Guam ALS and PD: An Evolutionary Process of Understanding
Current Alzheimer Research Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Excitotoxicity as a Target Against Neurodegenerative Processes
Current Pharmaceutical Design Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity
Current Neuropharmacology Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies
Current Alzheimer Research Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets